KMDA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

8.700

Open

8.700

VWAP

8.55

Vol

229.86K

Mkt Cap

493.22M

Low

8.410

Amount

1.97M

EV/EBITDA(TTM)

10.07

Total Shares

57.69M

EV

432.65M

EV/OCF(TTM)

15.28

P/S(TTM)

2.86

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

Show More

Events Timeline

(ET)

2026-03-11

16:30:00

Dow and S&P 500 Close Lower Amid Oil Price Volatility

2026-03-11

12:00:00

Dow Jones Drops Over 400 Points Amid Oil Price Volatility

2026-03-11

07:20:00

Kamada Reiterates 2026 Revenue Guidance of $200M to $205M

2026-03-11

07:10:00

Kamada Declares Cash Dividend of $0.25 per Share

2026-03-11

07:10:00

Kamada Reports 2025 Revenue of $180.5 Million, Up 12%

2026-01-07 (ET)

2026-01-07

07:10:00

Kamada Forecasts 2026 Revenue of $200M to $205M

2025-12-18 (ET)

2025-12-18

12:10:00

Major Averages Rise as CPI Report Released

2025-12-18

07:20:00

Kamada Reiterates 2025 Revenue Guidance of $178M to $182M

2025-12-18

07:20:00

Kamada Awarded $10M-$14M Contract Extension from Canadian Blood Services

News

Yahoo Finance

03-11Yahoo Finance

PinnedKamada Ltd Reports Strong 2025 Financial Results

seekingalpha

03-11seekingalpha

Kamada Declares $0.25 Cash Dividend Per Share

NASDAQ.COM

03-11NASDAQ.COM

Kamada Ltd. Reports Record 2025 Financial Results and Dividend Announcement

seekingalpha

03-11seekingalpha

Kamada Q4 Earnings Miss Expectations

seekingalpha

03-10seekingalpha

Kamada to Announce Q4 Earnings on March 11

Barron's

Analyst Predicts Increase in Hubspot Stock, Along with Insights on McGraw Hill, UHS, and Other Stocks.

2 Analyst Rating

Wall Street analysts forecast KMDA stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

13.00

Averages

14.00

High

15.00

Current: 0.000

Low

13.00

Averages

14.00

High

15.00

H.C. Wainwright

Buy

maintain

$11 -> $13

AI Analysis

2025-12-09

Reason

H.C. Wainwright

Price Target

$11 -> $13

AI Analysis

2025-12-09

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Kamada to $13 from $11 and keeps a Buy rating on the shares. The company decided to discontinue its Phase 3 inhaled alpha-1 antitrypsin deficiency clinical trial based on the results of the planned interim futility analysis, the analyst tells investors in a research note. The firm says the decision helps to refocus the company on its core products and eliminates a "long over-hanging distraction that was unlikely to be fruitful."

Benchmark

Robert Wasserman

Strong Buy

Initiates

$15

2025-03-21

Reason

Benchmark

Robert Wasserman

Price Target

$15

2025-03-21

Initiates

Strong Buy

Reason

Benchmark analyst Robert Wasserman initiated coverage of Kamada with a Buy rating and $15 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KMDA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Kamada Ltd (KMDA.O) is 16.25, compared to its 5-year average forward P/E of 4.33. For a more detailed relative valuation and DCF analysis to assess Kamada Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

4.33

Current PE

16.25

Overvalued PE

12.95

Undervalued PE

-4.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

4.97

Current EV/EBITDA

6.83

Overvalued EV/EBITDA

8.84

Undervalued EV/EBITDA

1.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

2.05

Current PS

2.09

Overvalued PS

2.59

Undervalued PS

1.50

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

find sideways stocks for iron condor short

Intellectia · 32 candidates

Rsi Category: moderateBeta: LowRisk, ModerateRiskMonth Price Change Pct: $-3.00 - $3.00Is Optionable: TrueOption Iv Rank: 40 - 80

Ticker

Name

Market Cap$

T-Mobile US Inc

220.78B

Abeona Therapeutics Inc

280.98M

Theravance Biopharma Inc

1.01B

Vertex Pharmaceuticals Inc

118.96B

Best Buy Co Inc

14.09B

Ross Stores Inc

62.42B

Intellectia · 36 candidates

Market Cap: 300.00M - 1.20BPrice: $5.00 - $20.00Quarter Revenue Yoy Growth: >= 5.0%Pe Ttm: 8 - 25Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Radiant Logistics Inc

304.37M

Hudson Technologies Inc

308.76M

Waterstone Financial Inc

322.63M

Nexxen International Ltd

369.34M

Ponce Financial Group Inc

373.91M

Colony Bankcorp Inc

394.00M

Whales Holding KMDA

Phoenix Investments & Finances Ltd

Trading Trends

People Also Watch

Frequently Asked Questions

What is Kamada Ltd (KMDA) stock price today?

The current price of KMDA is 8.55 USD — it has decreased -4.58

What is Kamada Ltd (KMDA)'s business?

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

What is the price predicton of KMDA Stock?

Wall Street analysts forecast KMDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KMDA is14.00 USD with a low forecast of 13.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Kamada Ltd (KMDA)'s revenue for the last quarter?

Kamada Ltd revenue for the last quarter amounts to 47.01M USD, increased 12.63

What is Kamada Ltd (KMDA)'s earnings per share (EPS) for the last quarter?

Kamada Ltd. EPS for the last quarter amounts to 0.09 USD, increased 28.57

How many employees does Kamada Ltd (KMDA). have?

Kamada Ltd (KMDA) has 374 emplpoyees as of March 12 2026.

What is Kamada Ltd (KMDA) market cap?

Today KMDA has the market capitalization of 493.22M USD.